LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

LLY

1,065.36

-0.14%↓

JNJ

229.36

-2.22%↓

ABBV

213.32

-1.3%↓

UNH

377.91

-2.64%↓

AZN

187.85

+0.32%↑

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

11.29 -5.44

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.22

Massimo

11.96

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.506 49.701
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+66.81% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.1B
Apertura precedente	16.73
Chiusura precedente	11.29

Notizie sul Sentiment di mercato

By Acuity

10%

90%

8 / 345 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mag 2026, 08:24 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mag 2026, 21:22 UTC

Utili

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mag 2026, 20:50 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:01 UTC

Discorsi di Mercato

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mag 2026, 14:43 UTC

Discorsi di Mercato

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mag 2026, 14:15 UTC

Discorsi di Mercato

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mag 2026, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

25 mag 2026, 12:58 UTC

Discorsi di Mercato

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mag 2026, 12:56 UTC

Discorsi di Mercato

Utili

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mag 2026, 12:34 UTC

Discorsi di Mercato

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mag 2026, 12:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 mag 2026, 11:00 UTC

Discorsi di Mercato

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mag 2026, 10:19 UTC

Discorsi di Mercato

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mag 2026, 10:05 UTC

Utili

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mag 2026, 10:04 UTC

Utili

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mag 2026, 10:03 UTC

Utili

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mag 2026, 10:02 UTC

Utili

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mag 2026, 10:01 UTC

Utili

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mag 2026, 10:00 UTC

Utili

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q EPS MYR0.1883

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Rev MYR17.1B

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Net MYR1.1B

25 mag 2026, 09:38 UTC

Discorsi di Mercato

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mag 2026, 08:55 UTC

Discorsi di Mercato

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

66.81% in crescita

Previsioni per 12 mesi

Media 20 USD 66.81%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

8 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.